Five to buy
GSK
GSK’s market value has fallen sharply recently owing to legal battles over its heartburn drug Zantac, which has been hit by fears that it increases the risk of cancer. The pharmaceutical giant has also faced criticism for its handling of mergers and Covid-vaccine development. However, GSK has been steadily improving its drug pipeline, increasing research and development (R&D) spending, “fattening up” its margins, and has a “chunky dividend yield
